Eflornithine

Care Team Contact Information: _____

Pharmacy Contact Information: _____

Diagnosis: _____

- This treatment is often used for neuroblastoma
- It may also be used for other reasons.

Goal of Treatment: _____

- Treatment may continue for a certain time period, until it no longer works, or until side effects are no longer controlled.

Treatment Regimen

Treatment Name	How the Treatment Works	How the Treatment is Given
Eflornithine (ee-FLOR-nih-theen): Iwilfin (i-WILL-fin)	Slows down or stops the growth of cancer cells by blocking proteins that help cancer cells survive and grow.	Tablets taken by mouth.

Treatment Administration and Schedule

Your eflornithine dosing instructions:

_____

_____

_____

- Eflornithine comes in 1 tablet strength: 192 mg.
- Your dose is based on many factors, including your height and weight, overall health, and diagnosis.
- Take eflornithine 2 times a day (about 12 hours apart) at about the same time each day.
- Take eflornithine with or without food.
- Swallow eflornithine tablets whole. If you cannot swallow tablets whole, eflornithine can be chewed, or crushed then mixed with soft food or liquid. If you are crushing eflornithine tablets:
  - Eflornithine can be crushed then mixed with 2 tablespoons of soft food or liquid.
  - Eat the entire mixture.
  - If any crushed tablet pieces remain, mix with another small amount (about 2 tablespoons) of soft food or liquid.
  - Take all of the mixture within 1 hour of mixing. Throw away any mixture left after 1 hour.

Brought to you by: ACCC Association of Cancer Care Centers, HOPA Hematology/Oncology Pharmacy Association, NCODA Network for Collaborative Oncology Development & Advancement, ONS Oncology Nursing Society

Treatment Administration and Schedule

- If you miss a dose of eflornithine, take it as soon as you remember. If it is within 7 hours of your next scheduled dose, skip the missed dose and take your next dose at your regular time.
- If you vomit after taking a dose, do not take an extra dose. Take your next dose at your regular time.
- If you take too much eflornithine, call your care team or go to the nearest hospital emergency room right away.

Storage and Handling of Eflornithine

- Store eflornithine at room temperature between 68°F and 77°F (20°C and 25°C) in a dry location away from light.
- Keep eflornithine and all medicines out of the reach of children and pets.
- People who are or may become pregnant should wear gloves when handling eflornithine.
- Ask your care team how to safely throw away any unused eflornithine.

Appointments: Appointments may include regular check-ups with your care team, lab visits, and imaging tests. It's important to keep your appointments whenever you can. If you miss any appointments, call your care provider as soon as possible to reschedule your appointment.

Supportive Care to Prevent and Treat Side Effects

Description	Supportive Care Taken at Home
Supportive care to prevent and treat side effects	

Brought to you by:
ACCC Association of Cancer Care Centers
HOPA Hematology/Oncology Pharmacy Association
NCODA Network for Collaborative Oncology Development & Advancement
ONS Oncology Nursing Society

Common Side Effects

Side Effect	Important Information
Ear Infection (Otitis Media)	Description: An ear infection can cause inflammation of the middle ear behind the eardrum. It can cause ear pain, pressure, fluid drainage, fever, and temporary hearing troubles. Recommendations: • Apply a warm compress to the ear to ease pain. • Avoid inserting anything into the ear. • Keep the ear dry; avoid swimming or getting water in the ear until your care team says it's okay. • Your care team may recommend or prescribe medicine for pain, fever, or to treat the infection. Talk to your care team if you have: • Ear pain • Ear drainage • Muffled hearing • Fever of 100.4°F (38°C) or higher • Significant hearing loss or sudden worsening of hearing

Select Rare Side Effects

Side Effect	Talk to Your Care Team if You Have Any of These Signs or Symptoms
Low White Blood Cell (WBC) Count (Neutropenia)	• Fever of 100.4 °F (38°C) or higher • Chills • Burning and painful urination • Urinating often • Weakness and tiredness • Coughing up yellow or pink mucus (phlegm)
Low Red Blood Cell (RBC) Count and Hemoglobin (Anemia)	• Fatigue • Weakness • Pale or dull skin • Shortness of breath • Dizziness or lightheadedness • Cold hands and feet • Irregular heartbeat • Headaches • Chest pain
Low Platelet Count (Thrombocytopenia)	• Bruising easily • Frequent nose bleeds • Blood in your urine or stool • Blood in your spit after a cough
Liver Problems	• Yellowing of your skin or the whites of your eyes • Severe nausea or vomiting, pain on the right side of your stomach area (abdomen) • Dark urine (tea colored) • Bleeding or bruising more easily than normal
Hearing Loss	• Difficulty understanding speech, especially in noisy environments • Asking others to repeat themselves frequently • Turning up the volume on devices • Struggling to hear people on the phone • Withdrawal from conversations or social situations • Ear ringing (tinnitus) • Feeling fullness or pressure in the ears

Brought to you by:
ACCC Association of Cancer Care Centers
HOPA Hematology/Oncology Pharmacy Association
NCODA Network for Collaborative Oncology Development & Advancement
ONS Oncology Nursing Society

Before starting treatment, ask your care team when to call 9-1-1 or seek emergency help.
If you experience any new, worsening, or uncontrolled side effects, contact your care team immediately.

Intimacy, Pregnancy, and Breastfeeding

- Treatment may **change how you feel about intimacy and your body.** However, physical closeness—such as holding hands and hugging—remains safe. It is common to have questions about intimacy. If needed, talk to your care team for guidance.
- Treatment may **harm an unborn baby**.
  - If you are able to become pregnant, take a pregnancy test before starting treatment.
  - Use an effective method of birth control during treatment and for 1 week after your last dose of eflornithine.
  - If you think you might be pregnant or if you become pregnant, tell your care team right away.
  - If your partner is able to become pregnant, use an effective method of birth control—such as condoms—during treatment and for 1 week after your last dose of eflornithine.
- **Do NOT breastfeed** during treatment and for 1 week after your last dose of eflornithine.

Additional Information

- **Tell your care team about all the medicines you take**.
  This includes prescriptions, over-the-counter drugs, vitamins, and herbal products. Before starting any new medicine, supplement, or vaccine, ask your care team first.
- **This Patient Education Sheet may not describe all possible side effects.**
  Call your care team for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Notes

Updated Date: April 30, 2026

Scan the QR code below to access this education sheet.

Important notice: The Association of Cancer Care Centers (ACCC), Hematology/Oncology Pharmacy Association (HOPA), Network for Collaborative Oncology Development & Advancement, Inc. (NCODA), and Oncology Nursing Society (ONS) have collaborated in gathering information for and developing this patient education guide. This guide represents a brief summary of the medication derived from information provided by the drug manufacturer and other resources.

Brought to you by: ACCC Association of Cancer Care Centers™ HOPA Hematology/Oncology Pharmacy Association NCODA Network for Collaborative Oncology Development & Advancement ONS Oncology Nursing Society

This guide does not cover all existing information related to the possible uses, directions, doses, precautions, warnings, interactions, adverse effects, or risks associated with this medication and should not substitute for the advice of a qualified healthcare professional. Provision of this guide is for informational purposes only and does not constitute or imply endorsement, recommendation, or favoring of this medication by ACCC, HOPA, NCODA, or ONS, who assume no liability for and cannot ensure the accuracy of the information presented. All decisions related to taking this medication should be made with the guidance and under the direction of a qualified healthcare professional.

Permission: Patient Education Sheets are provided as a free educational resource for patients with cancer and their caregivers in need of concise, easy to understand information about cancer therapy. Healthcare providers are permitted to copy and distribute the sheets to patients as well as direct patients to the Patient Education Sheets website. However, commercial reproduction or reuse, as well as rebranding or reposting of any type, are strictly prohibited without permission of the copyright holders. Permission requests, including direct linking from Electronic Health Records, and licensing inquiries should be emailed to patienteducationsheets@ncoda.org.

Copyright © 2026 by Network for Collaborative Oncology Development & Advancement, Inc. All rights reserved.

PES-352

Brought to you by: